Full-Time
Principal Scientist
Biologics Cell Line Development
Asimov
51-200 employees
Genetic design software with engineered cells
Compensation Overview
$170k - $190k/yr
Boston, MA, USA
In Person
PhD
 Biology & Biotech (2) |
|---|
| , |
Get referred to Asimov
See people who can refer or advise you
- At least 8 years of experience in CHO-based cell line development in an industrial cell line development environment, including expression of immunoglobulins and bispecifics.
- A Ph.D. in Biological Engineering, Cell Biology, Molecular Biology, or a related field.
- At least 1 year of experience managing direct reports and providing technical guidance.
- Ability to conduct and supervise CHO-based cell line development for biologic therapeutics moving into clinical development.
- Ability to design complex experimental approaches to improve expression systems and workflows through innovation and implementation of new technology.
- Perform CHO cell line development processes including transfection, cloning, characterization, and cell banking using state-of-the-art equipment.
- Drive innovation through the development of improved genetic components, host cell line engineering, and cell line development process optimization.
- Identify emerging practices for biologics cell line development and manufacturing to shape scientific strategies and continued innovation.
- Represent the cell line development team on cross-functional projects, make decisions for cell line activities, and communicate results, progress, and plans.
- Represent Asimov externally by contributing to industry conferences and forums, filing patents, and publishing peer-reviewed manuscripts.
- Manage and mentor a team of 3+ scientists focused on CHO-based biologics cell line development, provide technical direction, and support their professional development.
- Familiarity with vector optimization to improve titer and product quality attributes for complex bispecific scaffolds.
- Familiarity with cell line development process optimization.
- Familiarity with development of automated high-throughput screening for cell line development workflows.
- Experience working with a global customer base.
What Asimov does: It provides an integrated synthetic biology platform for biopharma, combining cloud-based software for designing, simulating, and optimizing genetic systems with engineered GMP host cells used for therapeutic production. How its products work: The software lets users design and run simulations of genetic circuits and optimize production processes, while engineered cell lines are used to express proteins or produce viral vectors; services include process development and stability studies. How it differs from competitors: It bundles an end-to-end suite—genetic design software, in-house cell-line development, and process development—along with a performance guarantee, such as a 4 g/L monoclonal antibody titer promise, reducing client risk. What its goal is: To help biopharma customers achieve high yields and scalable production of biologics, gene therapies, and programmable medicines through a tightly integrated platform.
Company Size
51-200
Company Stage
Series B
Total Funding
$204.7M
Headquarters
Boston, Massachusetts
Founded
2017
Get referred to Asimov
See people who can refer or advise you
Simplify's Take
What believers are saying
- 2026 partnerships with Kaigene, Score Pharma, and Kyungdong Pharmaceutical expand commercial validation.
- AGC Biologics licensed LV Edge in January 2026, extending distribution beyond Asimov’s labs.
- Asimov joined NSF’s Genesis Mission in July 2026 and launched RNA Edge.
What critics are saying
- Asimov still depends on biotech deal flow; a slowdown freezes revenue and hiring.
- Cytiva, AGC Biologics, and other CDMOs can bundle competing cell-line platforms.
- A failed flagship customer program, like Kaigene or Score Pharma, damages credibility quickly.
What makes Asimov unique
- Asimov’s CHO Edge combines GS knock-out hosts, transposase, parts libraries, and Kernel.
- Chrysalis transposase offers stable expression over 60 generations and faster cell recovery.
- Its platform spans cells, software, and lab-in-the-loop design across biologics, RNA, and gene therapies.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 2%2 year growth
↑ 0%BOSTON--(BUSINESS WIRE)--Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the expansion of its LV Edge System with the launch of a fully stable cell line development service. There are now two ways for customers to access Asimov’s cell line technology to minimize cost and manufacturing risk, depending on their needs:The LV Edge Packaging System, launched earlier this year, which enables a single plasmid transfection that achieves E8 TU/mL.The new, fully-stable LV Edge Producer cell line development service, which generates clones that achieve E9 TU/mL with no transient transfection required.The LV Edge Producer System completely eliminates GMP plasmid cost and greatly reduces process complexity and variability by stably integrating all the genes for lentiviral production into the host cell. Current processes for lentiviral production are inherently scale-limited and variable due to the need for multi-plasmid transient transfection. Furthermore, the reliance on GMP plasmids and transfection reagents substantially increases costs and introduces supply chain and product variability risks. The development of a fully stable cell line technology enables scalable, reproducible and low-cost production of lentivirus, which will unlock applications for larger therapeutic indications
The Foundry, formerly of MIT and the Broad Institute, has joined Asimov; its team, leadership, and infrastructure have moved to Asimov's Boston headquarters.headquarters. The group has nucleated Asimov Labs, a new R&D center for advanced genetic design.BOSTON, Aug. 2, 2023 /PRNewswire/ -- Asimov, the synthetic biology company building tools to design living systems, announced today that The Foundry, previously of MIT and the Broad Institute, has joined its ranks. The Foundry was established by Professor Christopher Voigt (MIT) in 2012 as part of DARPA's Living Foundries program to expand the limits of genetic design. During its tenure, the Foundry developed novel engineering techniques and used them to produce thousands of molecules, materials, genetic circuits, and sensors. In its new home at Asimov, the team will continue to pioneer genetic design as Asimov Labs, a center dedicated to developing technologies to open new frontiers for biological engineering.The Foundry, formerly of MIT and the Broad Institute, has joined AsimovAsimov develops cellular, genetic, and computational tools to enable next-generation therapeutics
LatchBio founders: Alfredo Andere, Kenny Workman, and Kyle Giffin. LatchBioMost industries today are experiencing an unprecedented data deluge – and synthetic biology is no exception. Twenty years ago, a typical biological experiment generated 3-5 megabytes of information. Today, a routine synthetic biology workflow produces anywhere from 1,000 to 40,000 terabytes. That is a billion times more data! Such a large number of data points is simply impossible to interpret by human eye. This is why almost every bio lab today has to set up custom bioinformatics pipelines, invest in cloud computing, and master advanced data visualization software – all that just to see the results of their experiments.A San Francisco startup, LatchBio, hopes to make data analysis much easier for biologists with its full-stack biocomputing infrastructure
Image/Anastasiia SlynkoThe companies Apogee Therapeutics, Pulmocide and Qitan Technology bagged the biggest biotech investments in December 2022. Around the world, immunology and manufacturing players attracted the biggest funding rounds.We’ve hit 2023 and a lot of biotech fundraising took place in the final month of 2022. We’ve gathered the biggest biotech investments that went to private companies around the world and split them into healthcare and industrial biotechnology-focused verticals.Healthcare investmentsThe U.S.’ top private biotech healthcare investment went to Apogee Therapeutics. The Paragon Therapeutics spinout took home $149 million in a Series B round to fund the development of drugs for a range of undisclosed immunological and inflammatory conditions.An honorable mention goes to Alpha9 Theranostics based in the U.S.’s neighbor, Canada. The firm raised $75 million in a bid to develop radiopharmaceutical treatments for cancer.The top European biotech healthcare investment round went to Pulmocide in the U.K. The firm’s $52 million Series C round will be used to finance the development of inhaled drugs treating viral and fungal infections in the respiratory tract.Content continues below Related ContentThe Chinese firm MaxVax topped the healthcare biotech investment list in Asia-Pacific with a $43 million investment in December 2022
“Before COVID, if I said we need to reproduce or scale, people would ask, why?” says Doug Densmore, Co-Founder of Lattice Automation and Asimov. “Now, people get it.” The consequence? An automated revolution in biotechnology, where cheap computing meets mass-reproducible synthetic biology, begetting an industry with the potential to surpass anything that went before it. The opportunity is […]